A Clinical Study to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell Lymphoma
To evaluate the efficacy and safety of TQB3702 tablets combined with immunochemotherapy for the treatment of B-cell lymphoma
B-cell Lymphoma
DRUG: TQB3702 tablets+Chemotherapy regimen
Overall response rate (ORR), According to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.the proportion of subjects whose tumors are evaluated as complete response(CR) and partial response(PR) by subcenter imaging evaluation. It is recorded from the first use of the drug to disease progression or initiation of a new anticancer treatment., Up to 2 years|Complete response rate (CRR), The rate of complete tumor remission, Up to 2 years
Adverse events (AE) and serious adverse events (SAE), Incidence and severity of adverse events (AE) and serious adverse events (SAE), as well as abnormal laboratory test indicators, Baseline to up to 28 days|ORR and CRR at the end of combination therapy, Objective response rate and complete remission rate at the end of combination therapy., Up to 1 year|Progression-free survival (PFS), PFS defined as the time from first dose to the first documented progressive disease (PD) or death from any cause., Up to 2 years|Duration of response (DOR), The period from the participants first achieving CR or PR to disease progression, Up to 2 years|Overall survival (OS), OS is defined as the time from the first administration to all-cause death, Up to all-cause death|1-year PFS and OS, 1-year Progression-free survival and Overall survival rates, Up to 1 year|2-years PFS and OS, 2-years Progression-free survival and Overall survival rates, Up to 2 years
To evaluate the efficacy and safety of TQB3702 tablets combined with immunochemotherapy for the treatment of B-cell lymphoma